Ewa Lewicka
Ewa Lewicka is an expert in Cardiology at University Clinical Centre (Poland). Ewa Lewicka has authored 177 publications, the most recent in 2026, and is an investigator in 5 clinical trials, 2 of them ongoing. SLR score: 551 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Internal Medicine - Biochemistry - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2007 - 2026
Number : 177
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Early and long-term outcomes and their predictors in incident pulmonary arterial hypertension: Results from the Database of Pulmonary Hypertension in Poland (BNP-PL). PMID 42708552 — heart defects, congenital, registries, hypertension, comorbidity, mortality, hypertension, pulmonary, heart diseases, hospitalization, heart, connective tissue, cardiovascular system, connective tissue diseases, cardiology, pulmonary arterial hypertension, diagnosis, therapeutics, tissues | Kardiol Pol | 2026 | 0 |
| Patients with cardiac implantable electronic devices undergoing radiation therapy for cancer or magnetic resonance imaging. PMID 42590958 — radiotherapy, cardiovascular system, neoplasms, magnetic resonance imaging, cardiology, therapeutics | Kardiol Pol | 2026 | 0 |
| Effectiveness of PAH Specific Treatment Is Comparable Between PAH Associated With Connective Tissue Disease and Idiopathic PAH: Data From the Multicentre National Registry. PMID 42516678 — registries, mortality, connective tissue, connective tissue diseases, therapeutics, tissues | Pulm Circ | 2026 | 0 |
| Hypertension is the most common cardiovascular risk factor in cancer patients - data from the CONNECT-POL registry. PMID 42417585 — registries, genes, pol, hypertension, lung, blood, breast neoplasms, cardiovascular system, neoplasms, blood pressure, prostate, cardiology, breast, cardiotoxicity, prevalence, risk factors, heart disease risk factors, cardio-oncology | Kardiol Pol | 2026 | 0 |
| Between cancer and the heart: Gated myocardial perfusion SPECT as a tool with moderate sensitivity and specificity in diagnostics for coronary artery disease in cardio-oncology patients. PMID 42257627 — coronary artery disease, heart, cardiovascular system, neoplasms, arteries, cardiology, tomography, emission-computed, single-photon, sensitivity and specificity, cardio-oncology | Kardiol Pol | 2026 | 0 |
Clinical Studies 5
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Reduced Dose Apixaban and Rivaroxaban Versus Low Molecular Weight Heparin in Patients With Hematologic Malignancies NCT07270263 — injections, cells, anticoagulants, enoxaparin, thromboembolism, embolism, safety, hematologic neoplasms, lymphoma, rivaroxaban, lymphoma, large b-cell, diffuse, neoplasms, heparin, leukemia, tablets, multiple myeloma, pulmonary embolism, venous thromboembolism, thrombosis, heparin, low-molecular-weight, injections, subcutaneous, b-lymphocytes, direct-acting oral anticoagulants, apixaban | N/A | Recruiting | 2024 |
| Sacubitril Valsartan in prevention of heart damage during breast cancer treatment 2024-517804-12-00 — valsartan, breast neoplasms, heart failure, heart, neoplasms, breast, cardiotoxicity, anthracyclines, primary prevention, therapeutics, cardiomyopathies | Phase 3 | Recruiting | 2024 |
LeadR Networks
Main global connection map